資料載入處理中...
臺灣人文及社會科學引文索引資料庫系統
:::
網站導覽
國圖首頁
聯絡我們
操作說明
English
行動版
(3.145.107.94)
登入
字型:
**字體大小變更功能,需開啟瀏覽器的JAVASCRIPT,如您的瀏覽器不支援,
IE6請利用鍵盤按住ALT鍵 + V → X → (G)最大(L)較大(M)中(S)較小(A)小,來選擇適合您的文字大小,
如為IE7以上、Firefoxy或Chrome瀏覽器則可利用鍵盤 Ctrl + (+)放大 (-)縮小來改變字型大小。
來源文獻查詢
引文查詢
瀏覽查詢
作者權威檔
引用/點閱統計
我的研究室
資料庫說明
相關網站
來源文獻查詢
/
簡易查詢
/
查詢結果列表
/
詳目列表
:::
詳目顯示
第 1 筆 / 總合 1 筆
/1
頁
來源文獻資料
摘要
外文摘要
引文資料
題名:
乳癌病人使用Tamoxifen治療時間對其存活之影響
書刊名:
醫務管理期刊
作者:
歐子綺
/
常傳訓
/
黃純文
/
陳楚杰
/
呂友敏
作者(外文):
Ou, Tzu-chi
/
Chang, Chuan-hsun
/
Huang, Chun-wen
/
Chen, Chu-chieh
/
Lu, You-min
出版日期:
2019
卷期:
20:1
頁次:
頁1-14
主題關鍵詞:
乳癌
;
泰莫西芬
;
治療時間
;
存活
;
Breast cancer
;
Tamoxifen
;
TAM
;
Treatment time
;
Survival
原始連結:
連回原系統網址
相關次數:
被引用次數:期刊(0) 博士論文(0) 專書(0) 專書論文(0)
排除自我引用:0
共同引用:0
點閱:7
目的:本研究旨在探討2000年至2005年新發乳癌病人使用泰莫西芬(Tamoxifen, TAM)治療時間對其存活之影響。方法:本研究利用全民健康保險研究資料庫進行分析,以百分比呈現類別變項分佈情形,並以每千人年呈現TAM乳癌病人的全死因發生密度;推論性統計分析利用對數等級檢定評估不同治療時間乳癌病人的存活率。結果:研究期間新發乳癌病人共561位其平均年齡、Charlson Comorbidity Index(CCI)得分及治療時間分別為50.69歲,0.34分,3.29年;追蹤乳癌病人5,540人年共78個死亡,發生密度為14.08。Kaplan-Meier分析結果顯示,TAM治療時間越短存活率越低。控制其他變項後,獨立影響乳癌病人存活的因素有年別、年齡層別、CCI得分及治療時間類別。結論:乳癌病人接受TAM治療時間大於5年的存活率較2年以下及2至5年佳,相關單位應向民眾宣導勿擅自停藥,以延長乳癌病人的存活時間。
以文找文
Objectives: The purpose of this study is to explore the impact of Tamoxifen treatment time on new-onset breast cancer patients on their survival from 2000 to 2005. Methods: This study used the National Health Insurance research database released by the National Health Research Institute (NHRI) and the distributions of category variables were presented as percentages. Then, the densities of breast cancer patient mortality were presented per 1,000 persons. Evaluation of survival rate of breast cancer patients at different treatment times using a log- rank test. Results: From 2000 to 2005, there were 561 patients newly diagnosed with breast cancer. In terms of basic data, the patients' average age, Charlson Comorbidity Index score and treatment time were 50.69 years, 0.34 points, and 3.29 years, respectively. In terms of the densities of incidences of all causes of death, tracking 78 cancer deaths in 5,540 person-years of breast cancer patients (the incidence density was 14.08 per 1,000 person-years). Kaplan-Meier's analysis results showed that the shorter the TAM treatment time, the lower the survival rate. After exerting control on the other variables, the factors independently affecting the survival of breast cancer patients in the TAM group include: year, age bracket, CCI category, and treatment time category. Conclusions: The survival rate of treatment times more than 5 years is better than that of less than 2 years and 2 to 5 years. Relevant agencies should advocate to the general public not to arbitrarily stop medications in order to prolong the survival time of breast cancer patients.
以文找文
期刊論文
1.
郭文宏(20130700)。乳癌的荷爾蒙治療。臺灣醫學,17(4),397-403。
延伸查詢
2.
陳昭姿(20090800)。Letrozole (Femara®)--乳癌荷爾蒙療法的理想選項。當代醫學,36(8)=430,619-623。
延伸查詢
3.
楊媛婷(2016)。淺談乳癌荷爾蒙療法之概況。彰基藥訊,24(3),1-4。
延伸查詢
4.
Davies, C.、Pan, H.、Peto, R.(2017)。10 vs 5 years of adjuvant tamoxifen: Exclusion of 1/402 centres in ATLAS。The Lancet,389(10082),1884。
5.
Davies, C.、Pan, H.、Godwin, J.、Gray, R.、Arriagada, R.、Raina, V.、Peto, R.(2013)。Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial。The Lancet,381(9869),805-816。
6.
Early Breast Cancer Trialists' Collaborative Group(1998)。Tamoxifen for early breast cancer: an overview of the randomised trials。The Lancet,351(9114),1451-1467。
7.
Early Breast Cancer Trialists' Collaborative Group(2005)。Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials。The Lancet,365(9472),1687-1717。
8.
Early Breast Cancer Trialists' Collaborative Group(2011)。Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials。The lancet,378(9793),771-784。
9.
Fisher, B.、Dignam, J.、Bryant, J.、Wolmark, N.(2001)。Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial。Journal of the National Cancer Institute,93(9),684-690。
10.
Hankinson, S. E.、Colditz, G. A.、Willett, W. C.(2004)。Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones。Breast Cancer Research,6(5),213-218。
11.
Hsieh, K. P.、Chen, L. C.、Cheung, K. L.、Chang, C. S.、Yang, Y. H.(2014)。Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women--an Asian population-based study。Public Library of Science One,9(2),e87027。
12.
Johnston, S. R.、Dowsett, M.(2003)。Aromatase inhibitors for breast cancer: Lessons from the laboratory。Nature Reviews Cancer,3(11),821-831。
13.
Khalis, M.、Charbotel, B.、Chajes, V.、Rinaldi, S.、Moskal, A.、Biessy, C.、Elfakir, S.(2018)。Menstrual and reproductive factors and risk of breast cancer: A case-control study in the Fez region, Morocco。PloS One,13(1),e0191333。
14.
Peto, R.(1996)。Five years of tamoxifen--or more?。Journal of the National Cancer Institute,88(24),1791-1793。
15.
Tormey, D. C.、Gray, R.、Falkson, H. C.(1996)。Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer。Journal of the National Cancer Institute,88(24),1828-1833。
研究報告
1.
衛生福利部統計處(2017)。105年國人死因統計結果分析。
延伸查詢
2.
衛生福利部中央健保署(2016)。全民健保特約醫療院所數。
延伸查詢
其他
1.
National Comprehensive Cancer Network(2016)。About the NCCN clinical practice guidelines in oncology (NCCN Guidelines®),https://www.nccn.org/professionals/default.aspx, 。
推文
當script無法執行時可按︰
推文
推薦
當script無法執行時可按︰
推薦
引用網址
當script無法執行時可按︰
引用網址
引用嵌入語法
當script無法執行時可按︰
引用嵌入語法
轉寄
當script無法執行時可按︰
轉寄
top
:::
相關期刊
相關論文
相關專書
相關著作
熱門點閱
1.
內在與外緣間異質身體:詮釋乳癌第一、二期存活者心理經驗現象
無相關博士論文
無相關書籍
無相關著作
1.
類風溼性關節炎與骨關節炎病患發生憂鬱症之風險比較
2.
腦下垂體瘤行切除手術之成本效果分析
3.
醫師聲望影響因素與口碑傳播之關係--以某醫院員工為例
4.
癌症病人中斷回診追蹤之因素探討
5.
臨床醫護人員對敗血症早期症狀與早期目標導向治療之認知度與執行度之探討
6.
利用谷歌地圖呈現醫院層級間三高處方用藥重複率改善結果的比較
7.
探討醫護人員對醫療及給藥錯誤告知之態度及障礙
8.
某醫學中心加護病房運用Hendrich II跌倒風險評估量表之現況探討
9.
以醫療區為基礎之流感併發重症疫情監控系統
10.
美容醫學競爭力指標建構之研究--以臺南地區為例
11.
支援群組協同合作功能的家屬健康照顧管理服務系統研發
12.
Investor Type, Options, and Mental Accounting: Evidence from the Taiwan Index Options Trading
13.
Cross Hedging Index Exchange Traded Funds in Taiwan: An Asymmetric Rotated ARCH Approach
14.
Herding and Systematic Trading Behavior: An Empirical Study of the TAIEX Options Market
15.
長照2.0服務據點規劃之研究:以屏東縣為例
QR Code